SEC Form 4 · accession 0001209191-15-057197
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Pomerantz
Officer — President and CEO · Director
Period of report
Jun 26, 2015
Accepted (ET)
Jun 29, 2015 · 5:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 26, 2015 | C | 22,727 | — | A | 22,727 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred StockF1 | — | Jun 26, 2015 | C | 22,727 | D | — | — | Common Stock | 22,727 | 0 | D |
Explanation of responses
- F1The Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis and had no expiration date.